Research and Markets (http://www.researchandmarkets.com/research/hz6xmm/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Dry (Atrophic) Macular Degeneration Overview
  3. Therapeutics Development
  4. Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview
  5. Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis
  6. Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies
  7. Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
  8. Dry (Atrophic) Macular Degeneration - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Dry (Atrophic) Macular Degeneration - Products under Development by Companies
  13. Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes
  14. Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development
  • Aciont Inc.
  • Acucela Inc.
  • Alexion Pharmaceuticals, Inc.
  • Alimera Sciences, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Benitec Biopharma Limited
  • Catalyst Biosciences, Inc.
  • Cell Cure Neurosciences, Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Genentech, Inc.
  • GenSight Biologics SA
  • GlaxoSmithKline Plc
  • Icon Bioscience, Inc.
  • MacuCLEAR, Inc.
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • Ophthotech Corp.
  • pSivida Corp.
  • R-Tech Ueno, Ltd.
  • StemCells, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • U.S. Stem Cell, Inc.

For more information visit http://www.researchandmarkets.com/research/hz6xmm/dry_atrophic